Archives of Clinical Infectious Diseases

Published by: Kowsar

In vitro Antifungal Susceptibility Testing of Clinical and Environmental Fusarium Isolates in Iran

Hamed Aghaei 1 , Parivash Kordbacheh 1 , Reza Kachuei 2 , Shahram Mahmoudi 1 , 3 , Setareh Agha Kuchak Afshari 1 , Mahin Safara 1 and Farideh Zaini 1 , *
Authors Information
1 Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 Molecular Biology Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
3 Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
Article information
  • Archives of Clinical Infectious Diseases: April 2018, 13 (2); e58976
  • Published Online: April 8, 2018
  • Article Type: Research Article
  • Received: April 23, 2017
  • Revised: July 28, 2017
  • Accepted: September 19, 2017
  • DOI: 10.5812/archcid.58976

To Cite: Aghaei H, Kordbacheh P, Kachuei R, Mahmoudi S, Agha Kuchak Afshari S, et al. In vitro Antifungal Susceptibility Testing of Clinical and Environmental Fusarium Isolates in Iran, Arch Clin Infect Dis. 2018 ; 13(2):e58976. doi: 10.5812/archcid.58976.

Abstract
Copyright © 2018, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev. 1994;7(4):479-504. [PubMed: 7834602]. [PubMed Central: PMC358338].
  • 2. Guarro J. Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment. Eur J Clin Microbiol Infect Dis. 2013;32(12):1491-500. doi: 10.1007/s10096-013-1924-7. [PubMed: 23934595].
  • 3. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis. 2002;35(8):909-20. doi: 10.1086/342328. [PubMed: 12355377].
  • 4. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20(4):695-704. doi: 10.1128/CMR.00014-07. [PubMed: 17934079]. [PubMed Central: PMC2176050].
  • 5. Wickern GM. Fusarium allergic fungal sinusitis. J Allergy Clin Immunol. 1993;92(4):624-5. [PubMed: 8409122].
  • 6. Gupta AK, Drummond-Main C, Cooper EA, Brintnell W, Piraccini BM, Tosti A. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66(3):494-502. doi: 10.1016/j.jaad.2011.02.038. [PubMed: 21820203].
  • 7. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol. 2000;42(2 Pt 1):217-24. doi: 10.1016/S0190-9622(00)90129-4. [PubMed: 10642676].
  • 8. Fallah B, Zaini F, Daei Ghazvini R, Kachuei R, Kordbacheh P, Safara M, et al. The antagonistic effects of Candida parapsilosis on the growth of Fusarium species and fumonisin production. Curr Med Mycol. 2016;2(1):1-6. doi: 10.18869/acadpub.cmm.2.1.1. [PubMed: 28681005]. [PubMed Central: PMC5490290].
  • 9. Goswami RS, Kistler HC. Heading for disaster: Fusarium graminearum on cereal crops. Mol Plant Pathol. 2004;5(6):515-25. doi: 10.1111/j.1364-3703.2004.00252.x. [PubMed: 20565626].
  • 10. Ghiasian SA, Kord-Bacheh P, Rezayat SM, Maghsood AH, Taherkhani H. Mycoflora of Iranian maize harvested in the main production areas in 2000. Mycopathologia. 2004;158(1):113-21. [PubMed: 15487329].
  • 11. Alastruey-Izquierdo A, Cuenca-Estrella M, Monzon A, Mellado E, Rodriguez-Tudela JL. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother. 2008;61(4):805-9. doi: 10.1093/jac/dkn022. [PubMed: 18263569].
  • 12. Al-Hatmi AM, van Diepeningen AD, Curfs-Breuker I, de Hoog GS, Meis JF. Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother. 2015;70(4):1068-71. doi: 10.1093/jac/dku505. [PubMed: 25538167].
  • 13. Azor M, Gene J, Cano J, Guarro J. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob Agents Chemother. 2007;51(4):1500-3. doi: 10.1128/AAC.01618-06. [PubMed: 17220423]. [PubMed Central: PMC1855466].
  • 14. Araujo R, Oliveira M, Amorim A, Sampaio-Maia B. Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification. Eur J Clin Microbiol Infect Dis. 2015;34(7):1289-301. doi: 10.1007/s10096-015-2374-1. [PubMed: 25894985].
  • 15. Al-Hatmi AM, Meletiadis J, Curfs-Breuker I, Bonifaz A, Meis JF, De Hoog GS. In vitro combinations of natamycin with voriconazole, itraconazole and micafungin against clinical Fusarium strains causing keratitis. J Antimicrob Chemother. 2016;71(4):953-5. doi: 10.1093/jac/dkv421. [PubMed: 26702918].
  • 16. Scheel CM, Hurst SF, Barreiros G, Akiti T, Nucci M, Balajee SA. Molecular analyses of Fusarium isolates recovered from a cluster of invasive mold infections in a Brazilian hospital. BMC Infect Dis. 2013;13:49. doi: 10.1186/1471-2334-13-49. [PubMed: 23363475]. [PubMed Central: PMC3579725].
  • 17. Castro Lopez N, Casas C, Sopo L, Rojas A, Del Portillo P, Cepero de Garcia MC, et al. Fusarium species detected in onychomycosis in Colombia. Mycoses. 2009;52(4):350-6. doi: 10.1111/j.1439-0507.2008.01619.x. [PubMed: 18793261].
  • 18. Balajee SA, Borman AM, Brandt ME, Cano J, Cuenca-Estrella M, Dannaoui E, et al. Sequence-based identification of Aspergillus, fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J Clin Microbiol. 2009;47(4):877-84. doi: 10.1128/JCM.01685-08. [PubMed: 19073865]. [PubMed Central: PMC2668331].
  • 19. Mohammadi A, Shams-Ghahfarokhi M, Nazarian-Firouzabadi F, Kachuei R, Gholami-Shabani M, Razzaghi-Abyaneh M. Giberella fujikuroi species complex isolated from maize and wheat in Iran: distribution, molecular identification and fumonisin B1 in vitro biosynthesis. J Sci Food Agric. 2016;96(4):1333-40. doi: 10.1002/jsfa.7227. [PubMed: 25903322].
  • 20. Ahmadi B, Mirhendi H, Makimura K, de Hoog GS, Shidfar MR, Nouripour-Sisakht S, et al. Phylogenetic analysis of dermatophyte species using DNA sequence polymorphism in calmodulin gene. Med Mycol. 2016;54(5):500-14. doi: 10.1093/mmy/myw004. [PubMed: 26868901].
  • 21. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013;30(12):2725-9. doi: 10.1093/molbev/mst197. [PubMed: 24132122]. [PubMed Central: PMC3840312].
  • 22. Clinical and Laboratory Standards Institute . Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. 2nd ed. Wayne, Pa: CLSI; 2008.
  • 23. Al-Hatmi AM, Bonifaz A, Tirado-Sanchez A, Meis JF, de Hoog GS, Ahmed SA. Fusarium species causing eumycetoma: Report of two cases and comprehensive review of the literature. Mycoses. 2017;60(3):204-12. doi: 10.1111/myc.12590. [PubMed: 27928841].
  • 24. Chadeganipour M, Nilipour S, Ahmadi G. Study of onychomycosis in Isfahan, Iran. Mycoses. 2010;53(2):153-7. doi: 10.1111/j.1439-0507.2008.01679.x. [PubMed: 19298358].
  • 25. Aghamirian MR, Ghiasian SA. Onychomycosis in Iran: epidemiology, causative agents and clinical features. Nihon Ishinkin Gakkai Zasshi. 2010;51(1):23-9. [PubMed: 20185868].
  • 26. Hwang SM, Suh MK, Ha GY. Onychomycosis due to nondermatophytic molds. Ann Dermatol. 2012;24(2):175-80. doi: 10.5021/ad.2012.24.2.175. [PubMed: 22577268]. [PubMed Central: PMC3346908].
  • 27. O'Donnell K, Sutton DA, Fothergill A, McCarthy D, Rinaldi MG, Brandt ME, et al. Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J Clin Microbiol. 2008;46(8):2477-90. doi: 10.1128/JCM.02371-07. [PubMed: 18524963]. [PubMed Central: PMC2519483].
  • 28. Al-Hatmi AM, Meis JF, de Hoog GS. Fusarium: Molecular Diversity and Intrinsic Drug Resistance. PLoS Pathog. 2016;12(4). e1005464. doi: 10.1371/journal.ppat.1005464. [PubMed: 27054821]. [PubMed Central: PMC4824402].
  • 29. Azor M, Gene J, Cano J, Sutton DA, Fothergill AW, Rinaldi MG, et al. In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. Antimicrob Agents Chemother. 2008;52(6):2228-31. doi: 10.1128/AAC.00176-08. [PubMed: 18391027]. [PubMed Central: PMC2415809].
  • 30. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother. 2002;46(10):3298-300. [PubMed: 12234865]. [PubMed Central: PMC128790].
  • 31. Hassan AS, Al-Hatmi AM, Shobana CS, van Diepeningen AD, Kredics L, Vagvolgyi C, et al. Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Genus Fusarium Causing Human Keratomycosis in South India. Med Mycol. 2016;54(3):287-94. doi: 10.1093/mmy/myv105. [PubMed: 26705832].
  • 32. Tortorano AM, Richardson M, Roilides E, van Diepeningen A, Caira M, Munoz P, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014;20 Suppl 3:27-46. doi: 10.1111/1469-0691.12465. [PubMed: 24548001].
  • 33. Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54(10):4446-50. doi: 10.1128/AAC.00286-10. [PubMed: 20625156]. [PubMed Central: PMC2944599].
  • 34. Salah H, Al-Hatmi AM, Theelen B, Abukamar M, Hashim S, van Diepeningen AD, et al. Phylogenetic diversity of human pathogenic Fusarium and emergence of uncommon virulent species. J Infect. 2015;71(6):658-66. doi: 10.1016/j.jinf.2015.08.011. [PubMed: 26348828].
  • 35. Al-Hatmi AM, Hagen F, Menken SB, Meis JF, de Hoog GS. Global molecular epidemiology and genetic diversity of Fusarium, a significant emerging group of human opportunists from 1958 to 2015. Emerg Microbes Infect. 2016;5(12). e124. doi: 10.1038/emi.2016.126. [PubMed: 27924809]. [PubMed Central: PMC5180370].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments